Citation

BibTex format

@article{Sullivan:2022:ndt/gfab303,
author = {Sullivan, MK and Lees, JS and Drake, TM and Docherty, AB and Oates, G and Hardwick, HE and Russell, CD and Merson, L and Dunning, J and Nguyen-Van-Tam, JS and Openshaw, P and Harrison, EM and Baillie, JK and ISARIC4C, Investigators and Semple, MG and Ho, A and Mark, PB},
doi = {ndt/gfab303},
journal = {Nephrology Dialysis Transplantation},
pages = {271--284},
title = {Acute kidney injury in patients hospitalized with COVID-19 from the ISARIC WHO CCP-UK Study: a prospective, multicentre cohort study.},
url = {http://dx.doi.org/10.1093/ndt/gfab303},
volume = {37},
year = {2022}
}

RIS format (EndNote, RefMan)

TY  - JOUR
AB - BACKGROUND: Acute kidney injury (AKI) is common in coronavirus disease 2019 (COVID-19). This study investigated adults hospitalized with COVID-19 and hypothesized that risk factors for AKI would include comorbidities and non-White race. METHODS: A prospective multicentre cohort study was performed using patients admitted to 254 UK hospitals with COVID-19 between 17 January 2020 and 5 December 2020. RESULTS: Of 85 687 patients, 2198 (2.6%) received acute kidney replacement therapy (KRT). Of 41 294 patients with biochemistry data, 13 000 (31.5%) had biochemical AKI: 8562 stage 1 (65.9%), 2609 stage 2 (20.1%) and 1829 stage 3 (14.1%). The main risk factors for KRT were chronic kidney disease (CKD) [adjusted odds ratio (aOR) 3.41: 95% confidence interval 3.06-3.81], male sex (aOR 2.43: 2.18-2.71) and Black race (aOR 2.17: 1.79-2.63). The main risk factors for biochemical AKI were admission respiratory rate >30 breaths per minute (aOR 1.68: 1.56-1.81), CKD (aOR 1.66: 1.57-1.76) and Black race (aOR 1.44: 1.28-1.61). There was a gradated rise in the risk of 28-day mortality by increasing severity of AKI: stage 1 aOR 1.58 (1.49-1.67), stage 2 aOR 2.41 (2.20-2.64), stage 3 aOR 3.50 (3.14-3.91) and KRT aOR 3.06 (2.75-3.39). AKI rates peaked in April 2020 and the subsequent fall in rates could not be explained by the use of dexamethasone or remdesivir. CONCLUSIONS: AKI is common in adults hospitalized with COVID-19 and it is associated with a heightened risk of mortality. Although the rates of AKI have fallen from the early months of the pandemic, high-risk patients should have their kidney function and fluid status monitored closely.
AU - Sullivan,MK
AU - Lees,JS
AU - Drake,TM
AU - Docherty,AB
AU - Oates,G
AU - Hardwick,HE
AU - Russell,CD
AU - Merson,L
AU - Dunning,J
AU - Nguyen-Van-Tam,JS
AU - Openshaw,P
AU - Harrison,EM
AU - Baillie,JK
AU - ISARIC4C,Investigators
AU - Semple,MG
AU - Ho,A
AU - Mark,PB
DO - ndt/gfab303
EP - 284
PY - 2022///
SN - 0931-0509
SP - 271
TI - Acute kidney injury in patients hospitalized with COVID-19 from the ISARIC WHO CCP-UK Study: a prospective, multicentre cohort study.
T2 - Nephrology Dialysis Transplantation
UR - http://dx.doi.org/10.1093/ndt/gfab303
UR - https://www.ncbi.nlm.nih.gov/pubmed/34661677
UR - https://academic.oup.com/ndt/article/37/2/271/6400122
UR - http://hdl.handle.net/10044/1/94930
VL - 37
ER -